×
AllNewsMapsImages Videos Shopping Books
Search tools

Merck Moves Past 50-Day Average: How to Play MRK Stock Now

Yahoo Finance
Merck MRK has reached a significant support level, making it an attractive option for investors from a technical standpoint.
11 hours ago

Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)

Business Wire
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION...
2 days ago

Solution Building: Merck Avoids One-Size-Fits-All Approach to AI and ML

Genetic Engineering and Biotechnology News
Iya Khalil, PhD, discusses Merck & Co.'s approach to artificial intelligence (AI), and success in applying the technology, with GEN Edge.
4 hours ago

Merck succeeds in late-stage study of PAH treatment (MRK:NYSE)

Seeking Alpha
Merck's late-stage study shows Winrevair significantly reduces health risks in PAH patients on double therapy. Read more here.
2 days ago

Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention

BioSpace
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that scientific and...
1 day ago

Merck's potential blockbuster cholesterol pill succeeds in late-stage studies

Reuters
Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of...
2 weeks ago

FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca

CNBC
The Food and Drug Administration approved Merck's shot designed to protect infants from respiratory syncytial virus during their first...
2 weeks ago

Merck held talks to buy Swiss biotech MoonLake for more than $3bn

Financial Times
The initial approach was rejected but talks could be revived, the people said. Merck's approach for US-listed MoonLake ahead of late-stage...
3 weeks ago

Exclusive: Kennedy's new vaccine adviser was expert witness against Merck vaccine

Reuters
One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an expert witness...
2 weeks ago

Two of Kennedy’s New ACIP Picks Were Paid Expert Witnesses in Merck Vaccine Cases

BioSpace
Martin Kulldorff and Robert Malone, both outspoken vaccine skeptics, have received compensation for their expert participation in various...
2 weeks ago